secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001193125-24-073294
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio reports Q4/FY2023 financials; first patient dosed with CABA-201 in myositis
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments $241.2M as of Dec 31, 2023, with runway into 1H26.
- R&D expenses $17.4M (Q4) and $55.4M (FY2023); G&A $5.7M (Q4) and $19.2M (FY2023).
- First patient dosed in Phase 1/2 RESET-Myositis trial; no CRS or ICANS observed in first 21 days.
- Initial clinical data from RESET-Myositis and RESET-SLE expected in 1H24; longer-term follow-up in 2H24.
- FDA granted Rare Pediatric Disease designation for CABA-201 in juvenile dermatomyositis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/0001193125-24-073294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/d717290d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-073294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer